LivaNova PLC trades on the Nasdaq stock exchange under the ticker symbol LIVN at approximately $80.14 per share.

LivaNova operates as a fully public enterprise, with its common shares listed and actively traded on the NASDAQ stock exchange under the ticker symbol LIVN.

LivaNova PLC officially became a publicly traded medical technology enterprise following the completion of a landmark cross-border corporate merger between Cyberonics and Sorin Group.

LivaNova is not strictly a domestic United States corporation, functioning instead as an international public enterprise legally incorporated and headquartered in London, United Kingdom.

LivaNova PLC is a global medical technology corporation headquartered in London, United Kingdom, dedicated to developing and delivering transformative cardiovascular and neuromodulation solutions for healthcare professionals worldwide.

Employee reviews for LivaNova generally reflect a mission-driven, highly collaborative corporate culture centered on developing advanced medical technologies for neuromodulation and cardiovascular care.

Sorin Group is officially part of LivaNova PLC, having completed a massive, high-profile cross-border business combination with United States-based medical device maker Cyberonics.

Equity research analysts evaluate LivaNova PLC (LIVN) with favorable long-term growth prospects, supported by its medical technology innovations centered on neuromodulation and cardiovascular systems.

LivaNova PLC, a global medical technology company headquartered in London, has reported consistent annual revenue growth reflecting the success of its specialized product lines in cardiac surgery and neuromodulation.

Live Oak Bank structures its digital business and personal savings accounts to eliminate standard monthly maintenance fees, allowing account holders to grow their deposits without seeing balances eroded by everyday administrative banking charges.

LivaNova, a prominent multinational medical device and technology company, faced a wave of class action lawsuits and public scrutiny following a major cybersecurity incident and data breach.

LivaNova PLC is a global medical technology company that designs, develops, and markets innovative medical devices for cardiovascular and neuromodulation therapies.

LivaNova’s total revenue is primarily derived from its two main business segments: Cardiopulmonary and Neuromodulation.

LivaNova PLC is an authentic, highly respected, and fully legitimate global medical technology enterprise that develops, manufactures, and markets innovative cardiovascular and neuromodulation devices.

Evaluating LivaNova as a long-term investment involves analyzing its market positioning in specialized medical device niches, ongoing clinical trial pipelines, and regulatory approval milestones.

LivaNova PLC is a global medical technology enterprise that designs, develops, and manufactures specialized cardiovascular and neuromodulation medical devices.

Equity research analysts covering LivaNova, trading under the ticker symbol LIVN, generally maintain balanced consensus recommendations leaning toward moderate buy or hold ratings.

Companies that operate similarly to LivaNova within the medical technology and neuromodulation space include specialized cardiovascular and neurological device manufacturers such as Medtronic, Boston Scientific, Abbott Laboratories, and Edwards Lifes...

Yes, Cyberonics is no longer an independent entity; it is now part of LivaNova PLC. LivaNova was formed in 2015 through the merger of Cyberonics and the Italian medical technology firm Sorin.

LivaNova maintains its official corporate incorporation and global executive headquarters in London, United Kingdom.

LivaNova PLC, a global medical technology enterprise specializing in the design, development, and distribution of cardiovascular and neuromodulation therapy systems—including advanced vagus nerve stimulation devices and cardiac surgery equipment—has ...